7 active not recruiting, 3 recruiting, 2 completed, 1 not yet recruiting. 13 Phase 2, 5 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Active not recruiting 7, Recruiting 3, Completed 2, Not yet recruiting 1 |
| Phase 1 | 5 | Recruiting 3, Active not recruiting 1, Not yet recruiting 1 |
Follow Refractory Ewing Sarcoma: new trials by email Literature Review of Refractory Ewing Sarcoma trials Research Report on Refractory Ewing Sarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12 - Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Children's Oncology Group | 79 | 2027-05-07 | 2026-09-22 |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma Lurbinectedin - Refractory Ewing Sarcoma, Relapsed Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | Jazz Pharmaceuticals | 60 | 2023-05-23 | 2026-11-05 |
| Elimusertib for the Treatment of Relapsed or Refractory Solid Tumors Elimusertib - Recurrent Alveolar Rhabdomyosarcoma, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 31 | 2021-12-22 | 2026-01-23 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint - Colorectal Carcinoma, Endometrial Carcinoma | Phase 1 / Phase 2 | Recruiting | Children's Oncology Group | 147 | 2021-11-08 | 2026-08-25 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma Onivyde, Talazoparib, Temozolomide - Recurrent Solid Tumor, Recurrent Ewing Sarcoma | Phase 1 / Phase 2 | Recruiting | St. Jude Children's Research Hospital | 90 | 2021-06-09 | 2026-05-19 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography - Hematopoietic and Lymphatic System Neoplasm, Recurrent Ependymoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1 | 2021-05-03 | 2026-11-13 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial Tipifarnib - Malignant Solid Neoplasm, Recurrent Adrenal Gland Pheochromocytoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 5 | 2020-10-13 | 2026-11-13 |
| Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial) Ivosidenib - Recurrent Ependymoma, Recurrent Ewing Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 3 | 2020-07-20 | 2026-11-13 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Pharmacokinetic Study, Ulixertinib - Advanced Malignant Solid Neoplasm, Recurrent Ependymal Tumor | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 20 | 2018-11-14 | 2026-11-13 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) Laboratory Biomarker Analysis, Palbociclib, Pharmacological Study - Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Completed | National Cancer Institute (NCI) | 23 | 2018-08-13 | 2026-04-03 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Advanced Malignant Solid Neoplasm, Ann Arbor Stage III Non-Hodgkin Lymphoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 1377 | 2017-07-31 | 2026-11-13 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Cabozantinib, Cabozantinib S-malate, Pharmacological Study - Adrenal Cortical Carcinoma, Alveolar Soft Part Sarcoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 109 | 2017-05-18 | 2026-11-13 |
| Eurosarc Trial of Linsitinib in Advanced Ewing Sarcoma Linsitinib - Relapsed Ewing Sarcoma, Refractory Ewing Sarcoma | Phase 2 | Completed | University of Oxford | 16 | 2014-03-01 | 2019-06-03 |
Sarcoma, Ewing (13) · Hepatoblastoma (9) · Osteosarcoma (9) · Rhabdomyosarcoma (9) · Sarcoma (9) · Wilms Tumor (9) · Neuroblastoma (8) · Lymphoma, Non-Hodgkin (7) · Neuroectodermal Tumors, Primitive, Peripheral (7) · Rhabdoid Tumor (7) · Ependymoma (6) · Glioma (6) · Histiocytosis, Langerhans-Cell (6) · Medulloblastoma (6) · Carcinoma, Hepatocellular (2)
Neoplasms by Histologic Type (13) · Neoplasms, Bone Tissue (13) · Neoplasms, Connective Tissue (13) · Neoplasms, Connective and Soft Tissue (13) · Neoplasms (12) · Myosarcoma (10) · Neoplasms, Muscle Tissue (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (9) · Female Urogenital Diseases (9) · Female Urogenital Diseases and Pregnancy Complications (9) · Genetic Diseases, Inborn (9) · Kidney Diseases (9) · Kidney Neoplasms (9) · Male Urogenital Diseases (9) · Neoplasms by Site (9)
Phantoms, Imaging (3) · Specimen Handling (3) · X-Rays (3) · Magnetic Resonance Spectroscopy (2) · Nuclear Medicine Department, Hospital (2) · ivosidenib (2) · palbociclib (2) · selpercatinib (2) · tipifarnib (2) · ulixertinib (2) · 3-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol (1) · Absorptiometry, Photon (1) · BAY 1895344 (1) · Biopsy (1) · Bone Density (1)
National Cancer Institute (NCI) (8) · Children's Oncology Group (2) · Jazz Pharmaceuticals (1) · St. Jude Children's Research Hospital (1) · University of Oxford (1)
United States (11) · Puerto Rico (6) · Canada (4) · Australia (3) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · United Kingdom (1)
Andrea T Franson (1) · Andrew B Hassan, BMBCh FRCP (1) · Christine A Pratilas (1) · Donald W Parsons (1) · Elizabeth D Alva (1) · Juan C Vasquez (1) · Kieuhoa T Vo (1) · Michael V Ortiz (1) · Rajen Mody (1) · Sara Federico, MD (1) · Sarah B Whittle (1) · Srivandana Akshintala (1)
PMID 31401903, PMID 33591402, PMID 35353553, PMID 38935895, PMID 39298716, PMID 41166674, PMID 42686334, PMID 42853672, PMID 42867148
U10CA180886 (7), UM1CA228823 (3)